Updated from 3:05 p.m. EDTHealth-related stock indices were mixed after the long holiday weekend Tuesday, as some stocks climbed with no announcements and others lagged on neutral-to-positive news. Qiagen ( QGEN - Get Report) announced on Tuesday that it signed a new licensing agreement with Germany's Epigenomics, expanding on one from 2005. The new agreement gives the Netherlands-based company the exclusive worldwide rights to Epigenomics' sample technologies for use in applied testing and in in-vitro molecular diagnostics. Epigenomics receives an upfront fee and further milestone payments and royalties, though precise financial terms weren't disclosed. A nonexclusive back-license also gives Epigenomics the rights to use the technologies in developmental projects and to commercialize in-vitro molecular diagnostics. Shares of Qiagen were up 28 cents, or 1.7%, to $17.21. Among those climbing on no apparent news were Affymetrix ( AFFX), which rose 77 cents, or 3%, to $26.26, and InterMune ( ITMN), which increased 66 cents, or 2.6%, to $26.05. Both stocks are part of the Amex Bioptechnology Index, which was up 6.39, or 0.8%, to 818.62. Micrus Endovascular ( MEND) said Tuesday that it received 510(k) clearance from the Food and Drug Administration for its Enzo steerable microcatheter. However, its stock was down 31 cents, or 1.5%, to $21.04.
Elan ( ELN) and Biogen Idec ( BIIB) announced that both the gastrointestinal drugs advisory and the drug safety and risk management advisory committees of the Food and Drug Administration will jointly review Crohn's disease treatment Tysabri on July 31. Biogen was down 26 cents, or 0.5%, to $49.21. Elan was down 14 cents, or 0.7%, to $19.19. An agreement between health-care services management company Hythiam ( HYTM) and Comprehensive Care Corp. ended a previous agreement and plan for a merger that entailed Hythiam's purchase of the remaining minority interest in CompCare. Hythiam said its current relationship provides all of the benefits it wants. CompCare will be an administrative services organization for Hythiam, while Hythiam continues to consolidate CompCare's financial results, according to the companies. Hythiam's shares were down 5 cents, or 0.7%, to $7.68. NeurogesX ( NGSX) said Tuesday that it appointed Jean-Jacques Bienaime to serve as chairman of its board. Bienaime is chief executive officer of BioMarin Pharmaceuticals ( BMRN). Shares of NeurogesX were up 3 cents, or 0.4%, to $8.